Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Benchmark Downgrades Emergent BioSolutions to Hold

Benchmark Downgrades Emergent BioSolutions to Hold

Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.

Analyst Ratings

Analyst Expectations for Cogent Biosciences’s Future

By Benzinga Insights

December 15, 10:00 AM

Within the last quarter, Cogent Biosciences (NASDAQ:COGT) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

COGT

Japan’s Semiconductor Push Aims to Bolster Nvidia’s Key Supplier TSMC With $10B Subsidy

By Anusuya Lahiri

October 25, 7:47 AM

Japan looks to dole out an additional 1.49 trillion yen ($10 billion) in subsidies for two key semiconductor projects.

AAPL

Salesforce Stock Is Tumbling Thursday: What’s Going On?

By Adam Eckert

May 30, 9:22 AM

Salesforce reported its first top-line miss in more than a decade late Wednesday, according to Benzinga Pro. Despite missing estimates, first-quarter revenue was up 11% on a year-over-year basis. Multiple analysts also lowered price targets on the stock following the print.

CRM